Amendments to and Listing of the Claims:

Please amend claims 33-39 and add new claims 42-50, without prejudice, as shown below in the following listing of all claims ever presented. The following listing of claims replaces all prior versions of the claims.

- 1-32. (Canceled)
- 33. (Currently Amended) A composition obtained by a process comprising reacting:
 - (i) a compound of the formula (I):

 $M_{3-n-p-2pr}[RuX_{6-n-p-q-2r}B_n(H_2O)_p(OH)_q(O)_r]_{2r+1}$ (I) wherein each M independently represents an alkali metal cation or ammonia, each B independently represents a monocyclic or multi-cyclic basic heterocycle with one or more nitrogen atoms imidazol, pyrazol, triazol or indazol, each X independently represents a halide, pseudo-halide, HCO_3 , or RCOO, in which R is a substituted or unsubstituted C_1 - C_6 -alkyl or C_2 - C_6 -alkenyl or a substituted or unsubstituted aryl, n=1 or 2, r=0, and each of p and q=0 or 1, or r=0.5 and each of p and q=0 or 0.5; and

(ii) a compound of the formula (II):

$$B'(HX')_S$$
 (II)

wherein B' represents a monocyclic or multi-cyclic basic heterocycle with one or more nitrogen atoms-imidazol, pyrazol, triazol or indazol, each X' independently represents a halide, pseudo-halide, HCO₃-, or RCOO-, in which R is hydrogen or a substituted or unsubstituted C₁-C₆-alkyl or C₂-C₆-alkenyl or a substituted or unsubstituted aryl, phosphate, sulphate, acetate, and s is an integer of 1 or more.

34. (**Currently Amended**) A composition according to claim 33, wherein the compound of the formula (I) is sodium *trans*-[tetrachlorobis(1H-indazol)-ruthenate (III)], and wherein the compound of formula (II) is indazolium hydrachloridehydrochloride.

7724883 2 of 11

- 35. (Previously Amended) A composition according to claim 33, wherein the molar ratio of the compound of the formula (I) to the compound of the formula (II) is 1:1.1.
- 36. (Previously Presented) A medicament comprising a composition according to claim 33.
- 37. (Currently Amended) A method of inhibiting treating a tumor activity comprising administering to a patient a composition according to claim 33, wherein the tumor is selected from the group consisting of a breast cancer, an ovarian cancer, a lung cancer, a colorectal tumor, a prostate cancer, a melanoma, a liver cancer, an astrocytoma, a neuroblastoma, a leukemia, an epidermoid carcinoma, a cervical carcinoma, a bladder carcinoma, an endometrioma, a tongue carcinoma, a glioblastoma, a lymphoid tumor, and a renal cell carcinoma.
 - 38. (Currently Amended) A composition comprising a mixture of:
 - (i) a compound of the general formula (III):

 $(B'H)_{3-n-p-2pr}[RuX_{6-n-p-q-2r}B_n(H_2O)_p(OH)_q(O)_r]_{2r+1}$ (III) wherein each of B and B' independently represents a monocyclic or multi-cyclic basic heterocycle with one or more nitrogen atoms-imidazol, pyrazol, triazol or indazol, each X independently represents a halide, pseudo-halide, HCO_3^- , or $RCOO^-$, in which R represents a substituted or unsubstituted C_1 - C_6 -alkyl or C_2 - C_6 -alkenyl or a substituted or unsubstituted aryl, n=1 or 2, r=0, and each of p and q=0 or 1, r=0.5 and each of p and q=0 or 0.5; and

(ii) a compound of the formula (VI):

wherein M represents an alkali metal cation or ammonia and X' represents a halide, pseudo-halide, HCO_3 , or RCOO, in which R is hydrogen or a substituted or unsubstituted C_1 - C_6 -alkyl or C_2 - C_6 -alkenyl or a substituted or unsubstituted aryl, phosphate, sulphate or acetate.

7724883 3 of 11

39. (**Currently Amended**) The <u>compound composition</u> according to claim 38, further comprising a compound of the formula (II):

$$B'(HX')_S$$
 (II)

wherein B' represents a monocyclic or multi-cyclic basic heterocycle with one or more nitrogen atoms-imidazol, pyrazol, triazol or indazol, each X' independently represents a halide, pseudo-halide, HCO₃-, or RCOO-, in which R is hydrogen or a substituted or unsubstituted C₁-C₆-alkyl or C₂-C₆-alkenyl or a substituted or unsubstituted aryl, phosphate, sulphate, acetate, and s is an integer of 1 or more.

40-41. (Canceled)

- 42. (New) The composition according to claim 33, wherein B is indazol.
- 43. (New) The composition according to claim 42, wherein B' is indazol.
- 44. (New) The composition according to claim 38, wherein B is indazol.
- 45. (New) The composition according to claim 44, wherein B' is indazol.
- 46. (New) The method according to claim 37, wherein the tumor is selected from the group consisting of an ovarian cancer, a lung cancer, a colorectal tumor, a prostate cancer, a melanoma, a liver cancer, an epidermoid carcinoma, a bladder carcinoma, an endometrioma, a tongue carcinoma, and a renal cell carcinoma.
- 47. (New) The method according to claim 46, wherein the tumor is an ovarian cancer or a colorectal tumor.
- 48. (New) A method of treating a tumor comprising administering to a patient a composition according to claim 38, wherein the tumor is selected from the group consisting of a breast cancer, an ovarian cancer, a lung cancer, a colorectal tumor, a prostate cancer, a melanoma, a liver cancer, an astrocytoma, a neuroblastoma, a leukemia, an epidermoid carcinoma, a cervical carcinoma, a bladder carcinoma, an endometrioma, a tongue carcinoma, a glioblastoma, a lymphoid tumor, and a renal cell carcinoma.

7724883 4 of 11

Application No. 10/627,519 Reply to Office Action of August 17, 2006

- 49. **(New)** The method according to claim 48, wherein the tumor is selected from the group consisting of an ovarian cancer, a lung cancer, a colorectal tumor, a prostate cancer, a melanoma, a liver cancer, an epidermoid carcinoma, a bladder carcinoma, an endometrioma, a tongue carcinoma, and a renal cell carcinoma.
- 50. (New) The method according to claim 49, wherein the tumor is an ovarian cancer or a colorectal tumor.

7724883 5 of 11